More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.23B
EPS
2.12
P/E ratio
8.9
Price to sales
2.99
Dividend yield
--
Beta
0.874159
Previous close
$18.75
Today's open
$18.84
Day's range
$18.59 - $19.44
52 week range
$15.86 - $30.96
show more
CEO
Catherine Owen Adams
Employees
798
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
172828972
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Acadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 Transcript
Acadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • 4 hours ago

Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP) during an oral presentation at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. Building on previously announced topline results, new analyses provided further evidence of a consistent efficacy signal with once.
Business Wire • 8 hours ago

Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercialization of DAYBUE® STIX (trofinetide) powder for oral solution in Japan for the treatment of Rett syndrome. Under the terms of the agreement, KYORIN will be responsible for leading the commercialization of DAYBUE STIX in Japan and the related regulatory activities on behalf of Acad.
Business Wire • Nov 16, 2026

Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delaware's May 2025 decision upholding Acadia's U.S. Patent No. 11,452,721 (the ‘721 patent), which covers the NUPLAZID® (pimavanserin) 34 mg capsule formulation. “We continue to believe in the strength of our position on the NUPLAZID formulation patent, on which t.
Business Wire • Nov 10, 2026

Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
SAN DIEGO, Calif.--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present two data presentations related to Alzheimer's disease psychosis (ADP) and remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16-19, 2026, in Boston. Acadia's presentations include an oral presentation featuring findings from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin in patients.
Business Wire • Nov 9, 2026

Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call
ACADIA Pharmaceuticals NASDAQ: ACAD reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and Parkinson's disease psychosis drug NUPLAZID drove growth.
MarketBeat • Nov 5, 2026

Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026. “Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build m.
Business Wire • Nov 4, 2026

Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.26 per share a year ago.
Zacks Investment Research • Nov 5, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell ACADIA Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.